BIND raises series C as nanoparticle anticancer reaches clinic
This article was originally published in Scrip
Executive Summary
BIND Biosciences has raised $12.4 million in a series C-1 financing in which all of its existing investors participated, including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments. They were joined by new investor Endeavour Vision.